2017年欧洲指南经验性治疗推荐对医院获得性肺炎的影响
该研究基于本中心6个ICU的前瞻性队列(507例)进行回顾性分析,仅纳入微生物学确诊的医院获得性肺炎患者315例,比较遵循与不遵循2017年欧洲指南经验性抗菌治疗算法的结局。总体两组结局相当,但遵循指南者过度治疗率更高(42.5% vs 66.3%,P < .001)。在无感染性休克亚组,遵循指南者ICU死亡率(28.8% vs 14.5%,P = .031)和校正28天死亡率(风险比3.07;95% CI,1.13-7.85;P = .027)均降低;合并感染性休克者则无获益。作者认为该算法对无感染性休克患者有效,对感染性休克患者无效。
要点
- 在无感染性休克的医院获得性肺炎患者中,遵循2017年欧洲指南经验性治疗算法与更低的ICU死亡率相关(28.8% vs 14.5%,P = .031)。
- 无感染性休克亚组中,未遵循指南者校正28天死亡风险更高(风险比3.07;95% CI,1.13-7.85;P = .027)。
- 在诊断时合并感染性休克的患者中,遵循指南与否未见获益。
- 总体人群中,遵循指南与更高的过度治疗率相关(42.5% vs 66.3%,P < .001),其余结局两组相当。
- 作者认为该算法对无感染性休克患者有效,对感染性休克患者无效,未来研究需明确是否需调整以改善感染性休克患者结局。
适用人群与场景
- 本中心6个ICU收治的医院获得性肺炎患者,仅纳入微生物学确诊者(315例)。
- 按诊断时是否存在感染性休克分为两个亚组进行分析。
诊断标准与关键阈值
- 医院获得性肺炎诊断需微生物学确诊。
- 按2017年欧洲指南算法,根据病史、本地生态和严重程度(即感染性休克的有无)决定经验性抗菌治疗。
处置流程与药物剂量
- 经验性抗菌治疗按2017年欧洲指南算法处方:依据病史、本地生态和严重程度(感染性休克有无)选择。
红旗征与不能漏的情况
- 诊断时存在感染性休克:该亚组中遵循指南未见获益。
研究设计与关键结果
- 研究类型:基于前瞻性队列(本中心6个ICU,507例)的回顾性分析;仅纳入微生物学确诊的医院获得性肺炎患者315例。
- 主要终点28天死亡率:遵循与不遵循指南两组相当。
- 次要终点90天死亡率、ICU死亡率、治疗不充分、治疗失败:两组相当;过度治疗率遵循指南组更高(42.5% vs 66.3%,P < .001)。
- 无感染性休克亚组:遵循指南者ICU死亡率更低(28.8% vs 14.5%,P = .031),校正28天死亡率更低(风险比3.07;95% CI,1.13-7.85;P = .027)。
- 感染性休克亚组:遵循指南未见获益。
证据类型、等级与局限
- 证据类型:基于前瞻性队列的回顾性分析(原文为retrospectively analyzed data from a prospective cohort)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,2017年欧洲指南经验性治疗算法对无感染性休克的医院获得性肺炎患者有效,可降低死亡率;对诊断时合并感染性休克的患者无效。
- 作者建议,未来研究应明确是否需调整该算法以改善感染性休克患者的结局。
指南或共识出处
- 2017年欧洲指南(European guidelines from 2017)
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The management of nosocomial pneumonia represents a major challenge in the ICU. European guidelines from 2017 proposed an algorithm for the prescription of empirical antimicrobial treatment based on medical history, local ecology, and severity (ie, presence or absence of septic shock). We assessed this algorithm's usefulness by comparing outcomes with and without guideline adherence in a population at high risk of multiresistance and mortality.
RESEARCH QUESTION: Are the recommendations of the latest European guidelines effective in reducing the incidence of adverse outcomes in patients with nosocomial pneumonia admitted to the ICU?
STUDY DESIGN AND METHODS: We retrospectively analyzed data from a prospective cohort of 507 patients from 6 ICUs in our center. To minimize bias, we only included patients with microbiologically confirmed pneumonia. The primary outcome was 28-day mortality. Secondary outcomes were 90-day mortality, ICU mortality, inadequate treatment, treatment failure, and overtreatment.
RESULTS: In total, 315 patients met the inclusion criteria. Outcomes were comparable in the groups with and without guideline adherence, except for overtreatment, which was higher when guidelines were followed (42.5% vs 66.3%; P < .001). In the subgroup without septic shock treated according to guidelines, reductions were noted in both ICU mortality (28.8% vs 14.5%; P = .031) and adjusted 28-day mortality (hazard ratio, 3.07; 95% CI, 1.13-7.85; P = .027). By contrast, no benefit was observed when patients presented with septic shock at diagnosis.
INTERPRETATION: Our findings indicate that the European guideline treatment algorithm is effective in reducing mortality in patients without septic shock but not in those with septic shock at the time of diagnosis. Future studies should clarify whether adjustments need to be made to improve outcomes in patients with septic shock.
参考来源
- Calabretta D, Cilloniz C, Gabarrus A, et al. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia. Chest. 2024. PMID: 39461555. doi:10.1016/j.chest.2024.10.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。